Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR, Sun E.

Antimicrob Agents Chemother. 2003 Jan;47(1):350-9.

2.

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Bergshoeff AS, Fraaij PL, Ndagijimana J, Verweel G, Hartwig NG, Niehues T, De Groot R, Burger DM.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):63-8.

PMID:
15851915
3.

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

Sáez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E, Pelton S, Ramilo O, Cahn P, Chadwick E, Allen U, Arpadi S, Castrejón MM, Heuser RS, Kempf DJ, Bertz RJ, Hsu AF, Bernstein B, Renz CL, Sun E.

Pediatr Infect Dis J. 2003 Mar;22(3):216-24.

PMID:
12634581
4.

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.

Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62.

5.

Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.

Goujard C, Vincent I, Meynard JL, Choudet N, Bollens D, Rousseau C, Demarles D, Gillotin C, Bidault R, Taburet AM.

Antimicrob Agents Chemother. 2003 Jan;47(1):118-23.

6.

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.

Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6.

PMID:
15980689
7.

Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, Engchanil C, Ruxrungtham K, Burger D; HIV-NAT 017 Study Team.

Pediatr Infect Dis J. 2005 Oct;24(10):874-9.

PMID:
16220084
8.

Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.

Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.

9.

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.

Antivir Ther. 2007;12(5):825-30.

PMID:
17713166
10.

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E.

Antivir Ther. 2002 Sep;7(3):165-74.

PMID:
12487383
11.

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

Solas C, Poizot-Martin I, Drogoul MP, Ravaux I, Dhiver C, Lafeuillade A, Allegre T, Mokhtari M, Moreau J, Lepeu G, Petit N, Durand A, Lacarelle B.

Br J Clin Pharmacol. 2004 Apr;57(4):436-40.

12.

Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.

Mallolas J, Pich J, Peñaranda M, Domingo P, Knobel H, Pedrol E, Gutiérrez F, Barrufet P, Peraire J, Asenjo MA, Vidal F, Gatell JM.

AIDS. 2008 Jan 30;22(3):377-84. doi: 10.1097/QAD.0b013e3282f3db2c.

PMID:
18195564
13.

Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.

Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.

Antivir Ther. 2007;12(6):963-9.

PMID:
17926651
14.

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.

Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chêne G, Clavel F, Girard PM.

Clin Pharmacol Ther. 2004 Apr;75(4):310-23.

PMID:
15060509
15.

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, Havens PL; PACTG 1038 Team.

Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08. Epub 2008 Jul 14.

16.

Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.

Panagopoulos P, Tsiodras S, Antoniadou A, Katsarolis I, Papadopoulos A, Poulakou G, Giamarellou H.

Clin Microbiol Infect. 2006 May;12(5):486-9.

17.

High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.

Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B.

HIV Clin Trials. 2007 Jul-Aug;8(4):193-204.

PMID:
17720659
18.

A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J.

Antivir Ther. 2003 Aug;8(4):279-87.

PMID:
14518696
19.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
20.

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.

AIDS. 2009 Sep 10;23(14):1829-40. doi: 10.1097/QAD.0b013e32832cbcec.

PMID:
19474650

Supplemental Content

Support Center